Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to longer than expected clinical development as well as competition from emerging novel injectable agents for the treatment of benign prostatic hyperplasia, Allergan's Botox will garner less market share than had been previously forecasted in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor 2010 finding from the topic entitled Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms reveals that the combined uptake of Nymox's NX-1207 and Protox Therapeutics' PRX-302, which are expected to launch in the United States and in Europe by 2014, will reduce Botox's expected market share in 2018 by more than half than was previously forecasted. However, the high cost of all three of these novel injectable therapies will limit their overall uptake in a market that is saturated with effective, well-established oral agents.

"We anticipate that novel injectable therapies will have only a small impact on the overall benign prostatic hyperplasia market as few patients will be switched from the oral medications they are currently receiving," said Decision Resources Analyst Benjamin Guikema, Ph.D. "Although Botox benefits from physician familiarity and brand recognition, we expect that injectable therapies for benign prostatic hyperplasia will be reserved for a niche group of patients with the most severe forms of the disease who would otherwise require minimally invasive treatments or surgery."

The Pharmacor 2010 findings also reveal that, through 2018 in the benign prostatic hyperplasia market, no agents from the gonadotropin-releasing hormone antagonist drug class will launch, following last month's discontinuation of AEterna Zentaris/Spectrum/Nippon Kayaku's ozarelix. On January 27, Spectrum Pharmaceuticals announced that it would end clinical development of ozarelix, owing to disappointing Phase II clinical trial results.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                     Decision Resources, Inc.   Gisselle Morales                       Christopher Comfort   781-296-2691                           781-296-2597       

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Gisselle Morales of Decision Resources, +1-781-296-2691,, or Christopher Comfort of Decision Resources, Inc.,

Genentech/Novartis Ophthalmics' Lucentis and Regeneron/Bayer's Aflibercept Will Become Decision Resources' Proprietary Clinical Gold Standard for the Treatment of Wet Age-Related Macular Degeneration in 2013

View Now